GAMMA Investing LLC Purchases 176,573 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

GAMMA Investing LLC raised its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 6,905.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 179,130 shares of the biopharmaceutical company's stock after purchasing an additional 176,573 shares during the quarter. GAMMA Investing LLC owned 0.11% of TG Therapeutics worth $7,063,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Vermillion Wealth Management Inc. bought a new stake in shares of TG Therapeutics during the 4th quarter valued at about $30,000. Quadrant Capital Group LLC lifted its position in shares of TG Therapeutics by 137.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock valued at $51,000 after buying an additional 975 shares in the last quarter. Blue Trust Inc. lifted its position in shares of TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 371 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of TG Therapeutics by 512.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after buying an additional 1,594 shares in the last quarter. Finally, Jones Financial Companies Lllp lifted its position in shares of TG Therapeutics by 460.7% during the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after buying an additional 1,737 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on TGTX. Wall Street Zen raised TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, TG Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $40.80.

TG Therapeutics Stock Up 1.9%

NASDAQ TGTX opened at $40.06 on Monday. The stock's 50 day moving average is $37.21 and its 200 day moving average is $34.69. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 12 month low of $15.16 and a 12 month high of $46.48. The stock has a market cap of $6.36 billion, a PE ratio of -400.56 and a beta of 1.94.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $120.86 million during the quarter, compared to analysts' expectations of $117.07 million. During the same period in the prior year, the firm posted ($0.07) earnings per share. The firm's revenue for the quarter was up 90.4% on a year-over-year basis. Research analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.